By Mill Chart
Last update: Aug 4, 2025
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) reported its second-quarter 2025 financial results, delivering a mixed performance relative to analyst expectations. The company’s revenue and earnings per share (EPS) figures diverged from estimates, prompting a modest market reaction in after-hours trading.
Following the earnings release, Syndax shares declined 3.66% in after-hours trading. This reaction may reflect profit-taking after a recent uptrend—the stock had gained 5.5% over the past two weeks and 10.9% over the past month. The revenue beat and narrower EPS loss did not immediately translate into a positive market response, suggesting investors may be weighing long-term sustainability against short-term outperformance.
Looking ahead, analysts project:
The company did not provide explicit forward guidance in its press release, making it difficult to assess whether these estimates align with management’s internal expectations.
The earnings update highlighted:
For a deeper dive into Syndax’s earnings and analyst estimates, visit the earnings page.
Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.
10.38
+0.4 (+4.01%)
Find more stocks in the Stock Screener